Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 1401 - 1425 of 1954 in total
MAHDL01 is a pharmaceutical combination of whole plants, which is used to increase the HDL/LDL ratio that improves overall cardiovascular health.
Investigational
DAR-0100A is under investigation in clinical trial NCT01466205 (Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder).
Investigational
Investigational
VGA039 is an IgG4 monoclonal antibody directed against protein S.
Investigational
Investigational
FCR001 is a somatic cell therapy product containing hematopoietic progenitor cells (HPC), Facilitating Cells (FC), and alpha beta T cells.
Investigational
Investigational
ASP-7317 consists of human embryonic stem cell-derived retinal pigment epithelium cells.
Investigational
M0002 is an orally-active selective vasopressin antagonist that inhibits water re-absorption from the kidneys. It is a vasopressin 2 antagonist and represents a new class of compounds – aquaretics – that produce profound diuresis without loss of electrolytes. It will be of major benefit to those patients not responding satisfactorily...
Investigational
ReN001 is a clonal human neural stem cell line developed for clinical use in the treatment of stable disability after stroke. ReN001 a strong candidate for one of the first cell-based IND applications to be submitted to the Food and Drug Administration in the United States for consideration for the...
Investigational
Investigational
TRC093 is a recombinant humanized IgG1k monoclonal antibody.
Investigational
Experimental
AMZ002 is a sterile injectable hormone developed as a purified synthetic polypeptide alternative to current FDA-approved epileptic seizure treatments.
Investigational
Investigational
Investigational
INM004, a Neutralizing Equine Anti-Stx Hyperimmune Immunoglobulin F(Ab')2 Fragment, is currently being investigated to treat Shiga-toxin producing bacterial infection relating to the prevention of hemolytic uremic syndrome.
Investigational
Apc001 is an aptamer developed for the treatment of osteogenesis imperfecta.
Investigational
MUL001 is live attenuated strain of Salmonella typhimurium being investigated for the treatment of schwannomas.
Investigational
WU-CART-007 consists of allogeneic, fratricide-resistant genetically modified T cells transduced with a 2nd generation 4-1BB-CD3z chimeric antigen receptor targeting human CD7.
Investigational
PRA023 is a humanized monoclonal antibody directed to vascular endothelial growth inhibitor, also known as tumour necrosis factor (TNF)-like ligand 1A (TL1A) and TNF superfamily member 15. It is being investigated for ulcerative colitis.
Investigational
Experimental
Matched Iupac: … {2,6}.0^{16,23}.0^{18,22}.0^{11,25}]pentacosa-3(24),4,6,8,10,12,14,16,18,20-decaen-4-yl]propanoic acid ... 10,15-diethenyl-5,9,14,19-tetramethyl-2,22,23,25-tetraaza-1-cobaltaoctacyclo[11.9.1.1^{1,8}.1^{3,21}.0^ …
NTLA-2002 is a lipid nanoparticle encapsulating single guide RNA (G012267) targeting the human KLKB1 gene and messenger RNA (mRNA000042) encoding Cas9. It is an investigational therapy designed to knock out the target gene kallikrein B1 (KLKB1) to reduce plasma kallikrein activity, thereby preventing hereditary angioedema attacks.
Investigational
Investigational
Nutraceutical
Matched Mixtures name: … HAMAZINC KREM ,90 G ... HAMEDERM PLUS %5,35 + %18 KREM, 90 GRAM …
Displaying drugs 1401 - 1425 of 1954 in total